{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T21:18:02Z","timestamp":1790543882574,"version":"4.1.0"},"reference-count":13,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,4,16]],"date-time":"2018-04-16T00:00:00Z","timestamp":1523836800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Osteoporosis and Sarcopenia"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1016\/j.afos.2018.04.001","type":"journal-article","created":{"date-parts":[[2018,4,27]],"date-time":"2018-04-27T01:40:45Z","timestamp":1524793245000},"page":"69-72","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Efficacy, safety, and compliance of ibandronate treatment for 3 years in postmenopausal Japanese women with primary osteoporosis"],"prefix":"10.1016","volume":"4","author":[{"given":"Takako","family":"Suzuki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukio","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.afos.2018.04.001_bib1","doi-asserted-by":"crossref","first-page":"16069","DOI":"10.1038\/nrdp.2016.69","article-title":"Postmenopausal osteoporosis","volume":"2","author":"Eastell","year":"2016","journal-title":"Nat Rev Discov Prim"},{"key":"10.1016\/j.afos.2018.04.001_bib2","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.jbspin.2009.10.001","article-title":"Osteoporosis in males and females: is there really a difference?","volume":"76","author":"Guggenbuhl","year":"2009","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.afos.2018.04.001_bib3","first-page":"153","article-title":"Once-yearly zoledronic acid in hip fracture prevention","volume":"4","author":"Demontiero","year":"2009","journal-title":"Clin Interv Aging"},{"key":"10.1016\/j.afos.2018.04.001_bib4","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1002\/jbmr.3337","article-title":"Vertebral fractures after discontinuation of denosumab: a post hoc analysis of the randomized placebo-controlled FREEDOM trial and its extension","volume":"33","author":"Cummings","year":"2018","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.afos.2018.04.001_bib5","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s00774-015-0731-x","article-title":"The effects of switching daily teriparatide to oral bisphosphonates or denosumab in patients with primary osteoporosis","volume":"35","author":"Ebina","year":"2017","journal-title":"J\u00a0Bone Miner Metabol"},{"key":"10.1016\/j.afos.2018.04.001_bib6","article-title":"Monthly oral ibandronate 100 mg is as effective as monthly intravenous ibandronate 1 mg in patients with various pathologies in the MOVEST study","author":"Hagino","year":"2017","journal-title":"J\u00a0Bone Miner Metabol"},{"key":"10.1016\/j.afos.2018.04.001_bib7","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1620\/tjem.241.319","article-title":"Alfacalcidol increases the therapeutic efficacy of ibandronate on bone mineral density in Japanese women with primary osteoporosis","volume":"241","author":"Nakamura","year":"2017","journal-title":"Tohoku J Exp Med"},{"key":"10.1016\/j.afos.2018.04.001_bib8","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s00223-013-9734-6","article-title":"Clinical efficacy on fracture risk and safety of 0.5 mg or 1 mg\/month intravenous ibandronate versus 2.5 mg\/day oral risedronate in patients with primary osteoporosis","volume":"93","author":"Nakamura","year":"2013","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.afos.2018.04.001_bib9","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s11657-012-0109-9","article-title":"Japanese 2011 guidelines for prevention and treatment of osteoporosis\u2013executive summary","volume":"7","author":"Orimo","year":"2012","journal-title":"Arch Osteoporos"},{"key":"10.1016\/j.afos.2018.04.001_bib10","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1007\/s00774-015-0723-x","article-title":"Effect of monthly intravenous ibandronate injections on vertebral or non-vertebral fracture risk in Japanese patients with high-risk osteoporosis in the MOVER study","volume":"35","author":"Ito","year":"2017","journal-title":"J\u00a0Bone Miner Metabol"},{"key":"10.1016\/j.afos.2018.04.001_bib11","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1001\/archinte.165.20.2414","article-title":"Compliance with osteoporosis medications","volume":"165","author":"Solomon","year":"2005","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.afos.2018.04.001_bib12","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/j.1524-4733.2007.00213.x","article-title":"Medication compliance and persistence: terminology and definitions","volume":"11","author":"Cramer","year":"2008","journal-title":"Value Health"},{"key":"10.1016\/j.afos.2018.04.001_bib13","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s11657-015-0231-6","article-title":"Compliance and persistence with daily, weekly, and monthly bisphosphonates for osteoporosis in Japan: analysis of data from the CISA","volume":"10","author":"Kishimoto","year":"2015","journal-title":"Arch Osteoporos"}],"container-title":["Osteoporosis and Sarcopenia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405525518300098?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405525518300098?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,7,9]],"date-time":"2018-07-09T12:28:23Z","timestamp":1531139303000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405525518300098"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6]]},"references-count":13,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["S2405525518300098"],"URL":"https:\/\/doi.org\/10.1016\/j.afos.2018.04.001","relation":{},"ISSN":["2405-5255"],"issn-type":[{"value":"2405-5255","type":"print"}],"subject":[],"published":{"date-parts":[[2018,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy, safety, and compliance of ibandronate treatment for 3 years in postmenopausal Japanese women with primary osteoporosis","name":"articletitle","label":"Article Title"},{"value":"Osteoporosis and Sarcopenia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.afos.2018.04.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Korean Society of Osteoporosis. Publishing services by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}